InMode Ltd. Ordinary Shares - INMD STOCK NEWS

InMode Ltd. (Nasdaq: INMD) has completed a significant IP transaction in the women's health and wellness market, acquiring all intellectual property assets of Viveve Medical Inc. This acquisition, along with an exclusive licensing agreement with the University of California, solidifies InMode's position as the global market leader in women's wellness products development.

InMode Ltd., a global provider of medical technologies, will release its financial results for Q2 2023 on July 27, 2023. Preliminary results show expected revenue of $135.7 million to $135.9 million for Q2 2023, non-GAAP earnings per diluted share of $0.70 to $0.71, and full-year revenue guidance of $530 million to $540 million. The non-GAAP gross margin for Q2 2023 is expected to be in the range of 83% to 85%.

InMode Ltd. announced their participation in several upcoming investor conferences and events. They will be presenting at the BNPP Exane Aesthetics Day, the Barclays West Coast Bus Trip, and the Jefferies Healthcare Conference. The presentations will be led by key executives including the CEO, CFO, and Chief Medical Officer. The events will include virtual fireside chats, in-person investor bus tours, and one-on-one meetings. Webcasts of the presentations will be available for replay and live access.

InMode Ltd. (INMD) announced the expected release of its first-quarter 2023 financial results on May 2, 2023, before the Nasdaq market opens. Preliminary estimates indicate revenue between $105.7 million and $105.9 million, and non-GAAP earnings per diluted share in the range of $0.50 to $0.51. The company anticipates a non-GAAP gross margin between 83% and 85%. The management team will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors are encouraged to register for the call ahead of time.

InMode Ltd. (NASDAQ: INMD) announced on March 13, 2023, that it does not hold cash or securities at Silicon Valley Bank. The company keeps its cash and non-insured deposits in U.S. money center banks and major Israeli financial institutions. Consequently, InMode does not anticipate any operational impact from the bank's closure. The company will continue to monitor potential effects on its suppliers, vendors, and other partners.

InMode is recognized for its innovative medical technologies, particularly those utilizing radiofrequency (RF) technology, serving various medical fields including plastic surgery and dermatology.

InMode Ltd. (NASDAQ: INMD), a global leader in innovative medical technologies, announced that its CFO Yair Malca and CMO Spero Theodorou will present at the Barclays Global Health Conference in Miami on March 15, 2023. The presentation is set for 9:30 am ET and will be moderated by equity research analyst Matt Miksic. Interested parties can access the webcast via InMode's Investor Relations website. InMode will also hold one-on-one investor meetings that day. For further details, visit the investor relations site.

InMode Ltd. (Nasdaq: INMD) reported record financial results for Q4 and FY 2022. Q4 revenue reached $133.6 million, a 21% increase from Q4 2021, with 83% from surgical technology platforms. GAAP net income for Q4 was $37.7 million, while non-GAAP net income hit $66.4 million. For the full year, revenues reached $454.3 million, a 27% increase, with GAAP net income of $161.5 million. Looking ahead, InMode forecasts revenue between $525 million and $530 million for 2023. Investors can expect a non-GAAP EPS of $2.58 to $2.60.

InMode Ltd. (Nasdaq: INMD) is set to announce its financial results for Q4 and the full year 2022 on February 14, 2023. Preliminary estimates indicate record revenues between $133.2 million and $133.4 million for Q4 2022, and $453.9 million to $454.1 million for the full year. Non-GAAP earnings per diluted share are expected to be $0.73 to $0.74 for Q4 and $2.38 to $2.39 for 2022. Additionally, the company projects 2023 revenues between $525 million and $530 million. InMode will hold a conference call on February 14 at 8:30 a.m. ET to discuss the results.